Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone

被引：0

作者：

Nanda, S. ^{[1
]}

Levin, V. ^{[1
]}

Martinez, M. W. ^{[1
]}

机构：

[1] Lehigh Valley Hlth Network, Div Cardiovasc Med, Allentown, PA 18103 USA

来源：

MINERVA CARDIOANGIOLOGICA | 2012年 / 60卷 / 06期

关键词：

Cardiomyopathy; hypertrophic; Death; sudden; cardiac; Dronedarone; Tachycardia; ventricular; ATRIAL-FIBRILLATION; AMIODARONE; HEART; REPERFUSION; ARRHYTHMIAS; PREVALENCE; SURVIVAL; ISCHEMIA; SR-33589; THERAPY;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hypertrophic cardiomyopathy (HCM) occurs in 1 in every 500 individuals. It represents the most common cause of sudden cardiac death in those under the age of twenty-five. 3-5% patients with HCM go on to develop the dilated, hypokinetic end stage (ES) HCM with systolic failure. They have a higher incidence of heart failure, sudden deaths and defibrillator shocks. To the best of our knowledge this is first report of successful use of dronedarone for suppression of VT associated with ES HCM.

引用

页码：637 / 641

页数：5

共 50 条

[21] Surgery of Hypertrophic Obstructive Cardiomyopathy in Patients With Severe Hypertrophy, Myocardial Fibrosis, and Ventricular Tachycardia
Borisov, Konstantin, V
ANNALS OF THORACIC SURGERY, 2018, 106 (01) : 30 - 37
[22] Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy
Killu, Ammar M.
Park, Jae-Yoon
Sara, Jaskanwal D.
Hodge, David O.
Gersh, Bernard J.
Nishimura, Rick A.
Asirvatham, Samuel J.
McLeod, Christopher J.
EUROPACE, 2018, 20 (01): : 82 - 88
[23] Genetic basis of end-stage hypertrophic cardiomyopathy
Garcia-Pavia, Pablo
Vazquez, Maria E.
Segovia, Javier
Salas, Clara
Avellana, Patricia
Gomez-Bueno, Manuel
Vilches, Carlos
Esther Gallardo, M.
Garesse, Rafael
Molano, Jesus
Bornstein, Belen
Alonso-Pulpon, Luis
EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (11) : 1193 - 1201
[24] Dramatic reduction of ventricular tachycardia burden after dronedarone plus mexiletine treatment in a patient refractory to hybrid ablation
Frutos-Lopez, Manuel
Pedrote, Alonso
Acosta-Martinez, Juan
Arana-Rueda, Eduardo
REVISTA PORTUGUESA DE CARDIOLOGIA, 2020, 39 (03) : 171 - 173
[25] Catheter ablation versus antiarrhythmic drug therapy for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy
Dong, Yan
Song, Xudong
Bo, Dan
Wang, Hongtao
Yang, Bo
Yadav, Nishant
Chen, Qiushi
Xu, Ruochen
Chen, Hongwu
Ju, Weizhu
Cao, Kejiang
Chen, Minglong
Zhang, Fengxiang
BMC CARDIOVASCULAR DISORDERS, 2024, 24 (01):
[26] Role of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Systematic Review and Updated Meta-Analysis of Risk Markers for Sudden Death
Bittencourt, Marcelo Imbroinise
Cader, Samaria Ali
Araujo, Denizar Vianna
Ferreira Salles, Ana Luiza
de Albuquerque, Felipe Neves
de Mello Spineti, Pedro Pimenta
de Albuquerque, Denilson Campos
Mourilhe-Rocha, Ricardo
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2019, 112 (03) : 281 - 289
[27] CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase
Cheng, Sainan
Choe, Yeon Hyeon
Ota, Hideki
Cui, Chen
Yin, Gang
Lu, Minjie
Li, Lu
Chen, Xiuyu
Prasad, Sanjay K.
Zhao, Shihua
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2018, 34 (04) : 597 - 605
[28] Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy
Harris, Kevin M.
Spirito, Paolo
Maron, Martin S.
Zenovich, Andrey G.
Formisano, Francesco
Lesser, John R.
Mackey-Bojack, Shannon
Manning, Warren J.
Udelson, James E.
Maron, Barry J.
CIRCULATION, 2006, 114 (03) : 216 - 225
[29] A Surgical Option for Ventricular Tachycardia Caused by Nonischemic Cardiomyopathy
Stevenson, William G.
Couper, Gregory S.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2011, 4 (04) : 429 - 431
[30] Successful treatment of end-stage hypertrophic cardiomyopathy with biventricular cardiac pacing
Pezzulich, B
Montagna, L
Lucchina, PG
EUROPACE, 2005, 7 (04): : 388 - 391

← 1 2 3 4 5 →